Keytruda

News
MSD says subcutaneous Keytruda matches IV form

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.